Shionogi & Co., Ltd. (OTCMKTS:SGIOY) Issues Quarterly Earnings Results

Shionogi & Co., Ltd. (OTCMKTS:SGIOY - Get Free Report) posted its quarterly earnings results on Monday. The company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.17 by ($0.03), Zacks reports. The company had revenue of $721.77 million during the quarter, compared to analysts' expectations of $824.23 million. Shionogi & Co., Ltd. had a return on equity of 12.02% and a net margin of 35.53%.

Shionogi & Co., Ltd. Trading Up 1.6%

SGIOY stock traded up $0.12 during trading on Friday, hitting $7.61. The company had a trading volume of 110,070 shares, compared to its average volume of 123,130. The firm has a market capitalization of $12.95 billion, a P/E ratio of 14.55, a PEG ratio of 2.37 and a beta of 0.19. Shionogi & Co., Ltd. has a 52-week low of $6.22 and a 52-week high of $8.72. The company has a 50 day simple moving average of $7.89 and a 200-day simple moving average of $7.39. The company has a quick ratio of 7.01, a current ratio of 7.64 and a debt-to-equity ratio of 0.01.

Shionogi & Co., Ltd. Company Profile

Shionogi & Co, Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug.